Bacil Pharma (524516) Q2 24/25 earnings summary

Executive summary

• Un-audited financial results for the quarter and half year ended 30th September 2024 were approved, showing a significant turnaround in profitability compared to the previous year.

• Board meeting concluded with approval of financial statements and routine business matters.

Financial highlights

• Revenue from operations for Q2 FY25 was ₹56.04 lakhs, up sharply from ₹2.88 lakhs in Q2 FY24.

• Profit after tax for Q2 FY25 stood at ₹48.40 lakhs, compared to a loss of ₹1.15 lakhs in Q2 FY24.

• EPS for Q2 FY25 was ₹0.82, versus negative EPS in the prior year quarter.

• Total assets increased to ₹186.17 lakhs as of 30th September 2024 from ₹132.61 lakhs as of 31st March 2024.

• Net cash from investing activities for H1 FY25 was ₹86.22 lakhs, offset by net cash outflow from financing activities of ₹71.37 lakhs.

Outlook and guidance

• Statutory auditors expressed an unmodified opinion on the financials, indicating no material misstatements.